Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
|Articles|December 7, 2021
Patients With End-Stage Renal Disease, Atrial Fibrillation Have Unique Considerations When Starting Anticoagulation Therapy
Assessing stroke benefit and net clinical benefit of anticoagulation is essential in patients with end-stage renal disease and atrial fibrillation.
Advertisement
In an interview with Pharmacy Times, Zachary Noel, PharmD, BCCP, discussed the presentation at the American Society of Health-System Pharmacists 2021 Midyear Meeting titled "Direct Oral Anticoagulant Dilemmas: Stroke Prevention for Atrial Fibrillation in the Oldest Old and Patients with End-Stage Renal Disease."
In the interview, Noel discussed specific considerations for patients with end-stage renal disease and atrial fibrillation, recommendations for anticoagulation initiation, and how to best assess stroke risk in these populations.
Advertisement
Related to this article
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
4
Can AI Help Predict Drug Shortages?
5